Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections by Steller, S. et al.
REGULAR ARTICLE
Bacterial protein microarrays for identification of new
potential diagnostic markers for Neisseria meningitidis
infections
Sigrid Steller1, Philipp Angenendt1, Dolores J. Cahill2, 3, 4, Sigrid Heuberger5,
Hans Lehrach1 and Jürgen Kreutzberger1
1 Max-Planck-Institute for Molecular Genetics, Berlin, Germany
2 Ruhr-University Bochum, Medical Proteome Center, Bochum, Germany
3 PROTAGEN AG, Dortmund, Germany
4 The Centre for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland
5 Nationale Referenzzentrale für Meningokokken, AGES BSU-Graz, Graz, Austria
Neisseria meningitidis is the most common cause of meningitis and causes epidemic outbreaks.
One trait of N. meningitidis, which is associated with most of the currently recognized virulence
determinants, is the presence of phase-variable genes that are suspected to enhance its ability to
cause an invasive disease. To detect the immune responses to phase-variable expressed proteins,
we applied protein microarray technology for the screening of meningitis patient sera. We
amplified all 102 known phase-variable genes from N. meningitidis serogroup B strain MC58 by
polymerase chain reaction and subcloned them for expression in Escherichia coli. With this
approach, we were able to express and purify 67 recombinant proteins representing 66% of the
annotated genes. These were spotted robotically onto coated glass slides to generate protein
microarrays, which were screened using 20 sera of patients suffering from meningitis, as well as
healthy controls. From these screening experiments, 47 proteins emerged as immunogenic,
exhibiting a variable degree of seroreactivity with some of the patient sera. Nine proteins elicited
an immune response in more than three patients, with one of them, the phase-variable opacity
protein OpaV (NMB0442), showing responses in 11 patient sera. This is the first time that protein
microarray technology has been applied for the investigation of genetic phase variation in patho-
gens. The identification of disease-specific proteins is a significant target in biomedical research,
as such proteins may have medical, diagnostic, and commercial potential as disease markers.
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1 Introduction
Neisseria meningitidis is the major causative agent of bacte-
rial meningitis. Over 500 000 meningococcal cases occur
each year, a number that is frequently accentuated by large
epidemic outbreaks especially in the African meningitis belt
[1]. These numbers have put bacterial meningitis into the
list of the top ten infectious causes of death worldwide.
N. meningitidis is an exclusively human commensal and
pathogen. To survive as a human upper respiratory com-
mensal and occasionally as a bloodstream invader, the
meningococcus has evolved novel and sophisticated genetic
mechanisms, most notably the phase variation. Many genes
are subject to phase variation, including pili [2], capsule [3],
outer membrane proteins [4, 5], hemoglobin receptors [6],
and lipooligosaccharides [7]. Phase variation has been pro-
posed to enhance the capacity of the organism to cause
invasive disease. Virji et al. [8, 9] showed in in vitro studies
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that adhesion to or particularly invasion of epithelial cells
were enhanced by the presence of certain opacity (Opa)
proteins.
Phase variable addition of sialic acid to capsular poly-
saccharides or lacto-N-neotetraose structures of lipopoly-
saccharides can occur with a frequency of 1023 – 1024 per
generation [10]. Phase variation of surface sialic acids is
involved in host invasion and may implicate phenotypic
transitions, so the sialization status is correlated to the three
phenotypes: transmission phenotype (sialylated), colonizing
phenotype (asialylated), and disseminating phenotype (sia-
lylated). In such a model of meningococcal pathogenesis,
Opa proteins may contribute significantly to host invasion
[3].
For N. meningitidis strain MC58, 102 putative phase-vari-
able genes were described, the largest repertoire of phase-
variable genes in any species to date [11]. The phase variation
process generally requires the presence of repeated nucleo-
tide tracts within the coding or the promoter region [12, 13].
Additionally, a new mechanism of phase variation was iden-
tified for nadA, in which a repeat tract was located upstream
of the putative 235 element of the nadA promoter [14]. The
instability of these repeats during replication can shift read-
ing frames or alter the strength of promoters, thus affecting
gene expression [15].
Identification of N. meningitidis is normally performed
after culturing the bacteria isolated from cerebrospinal fluid
(CSF), following biochemical investigation or antigen detec-
tion by latex agglutination. Sometimes the bacteria can be
identified in microscopic examinations of the spinal fluid.
The WHO postulates more specialized laboratory tests for
the identification of serogroups as well as for testing the
sensibility to antibiotics (WHO Fact sheet N7141; http://
www.who.int/mediacentre/factsheets/fs141/en/). PCR diag-
nosis has become of special interest, but has not been fully
established in routine laboratory use [16, 17]. Moreover, PCR
is not suited to describe the protein expression of phase-
variable expressed genes and to monitor the antibody con-
tent against these proteins in serum samples, which is the
aim of our study.
Miniaturized and parallel assay systems, especially
microarray-based analysis, are crucial to large-scale and high-
throughput biological analysis, as they are rapid and eco-
nomic to interpret gene function [18–20]. In the microarray
format, capture molecules are immobilized at highdensity
on a solid support, and probed for various biochemical activ-
ities. The microarray format has the advantage that thou-
sands of proteins can be screened simultaneously in an
automated fashion with very small consumption of serum.
In the past years several protein microarray methodologies
have been developed for the high-throughput investigation
of proteins. Some approaches applied cDNA expression
libraries [21–23], others employed antibodies or proteins for
the screening of interactions [24–31]. For example, protein
microarrays have been used for the analysis of autoantibody
responses to distinguish autoimmune diseases [32]. In this
study we used protein microarrays to identify N. meningitidis
proteins for potential diagnostic purposes.
2 Materials and methods
2.1 Choice of genes
All 102 phase-variable genes of N. meningitidis strain MC58
[12, 13] were selected for PCR amplification.
2.2 PCR
All primers had ten nucleotide adaptor regions containing a
restriction enzyme recognition site (XhoI in the 5’end,
Bsp120L in the 3’end) followed by a 21 nucleotides gene-spe-
cific part. Primer sequences for the adaptor sites were as fol-
lows: XhoI: GCC TCG AGG, Bsp120L: G GAT GGG CCC.
The 5’ primers were designed to be in-frame with the RGS-
His6 encoding reading frame. For genes annotated with an
authentic frameshift, resulting in the disruption of one sin-
gle ORF, we used two different strategies: for genes with an
ORF interruption near the 5’ end, we designed primers
binding 3’ of this interruption, resulting in one shortened
ORF. For genes with an interruption in the middle, we
designed two separate primer pairs flanking this disruption,
resulting in the generation of two recombinant proteins for
one disrupted gene. PCR amplification was performed with
Platinum Pfx DNA Polymerase (Invitrogen, Groningen, The
Netherlands). PCR was performed in 50 mL batches with a
reaction mixture containing 235 ng plasmid DNA, 10 pmol
primer, 10 mM dNTPs, and reaction buffer. PCR was per-
formed at 947C for 2 min, followed by 25 cycles of 947C for
30 s, 557C for 1 min, and 687C for 90 s and finished with a
final elongation at 687C for 7 min. PCR products were puri-
fied with a QIAquick PCR purification kit (Qiagen, Hilden,
Germany).
2.3 Cloning
Purified PCR products were digested with XhoI and Bsp120L
(using 50 U each) and ligated to the expression vector
pQE32-NST-BTattB (a derivative of pQE30NST; GI:3328183)
previously digested with NotI and SalI. The ligation mixture
was transformed into chemically-competent Escherichia coli
SCS1 cells harboring a pSE111 helper plasmid, carrying lacIq
and kanamycin resistance [21]. Cells were then grown for
16 h at 377C on Luria broth (LB) agar plates containing
ampicillin (100 mg/mL), kanamycin (25 mg/mL), and glucose
(5% w/v). Clones were picked and grown for 16 h at 377C on
LB plates as described above. Cells were harvested and plas-
mid DNA was isolated with a Qiagen BioRobot 8000 and the
MagAttract 96 Miniprep system. Isolated DNA was digested
with EcoRI, analyzed by agarose gel electrophoresis, and
positive clones were verified by sequencing.
 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de
Proteomics 2005, 5, 0000–0000 Protein Arrays 3
2.4 Protein expression and purification
Clones were grown for 16 h at 377C in deep-well microtiter
plates containing 1 mL LB medium with ampicillin (100 mg/
mL), kanamycin (25 mg/mL), and glucose (5% w/v). After
16 h, 200 mL culture medium was transferred to 2 mL LB
containing ampicillin (100 mg/mL) and kanamycin (25 mg/
mL). Protein expression was induced after 2.5 h incubation
at 377C by addition of isopropyl-b-D-thiogalactoside (IPTG)
(1 mM final concentration). Four hours after induction, the
cells were harvested by centrifugation at 15006 g for 15 min
at 47C. Protein purification was carried out with a Qiagen
BioRobot 8000 and the Ni-NTA Superflow 96 BioRobot Kit
using a protocol for purification under denaturing condi-
tions. Proteins were analyzed on a 12.5% polyacrylamide gel
containing SDS and their molecular weights were deter-
mined. The protein concentration was determined using the
Bradford assay [33].
2.5 Generation of protein microarrays
We used FAST Slides, which have a 14 mm thick NC-based
coating in a size of 20 mm6 50 mm (Schleicher & Schuell,
Dassel, Germany). Proteins or antibodies were spotted in a
46 4 pattern using a QArray system (Genetix, Hampshire,
UK) equipped with humidity control (60%) and 16 blunt
ended stainless steel print tips with a tip diameter of 150 mm.
Purified proteins were spotted in duplicate with a spot center
to center distance of 1250 mm in an uniform pattern in two
identical fields. In addition to N. meningitidis proteins, we
also spotted dilution series of unlabeled antibodies against
human IgG and IgM to normalize the microarrays.
2.6 Sera
In this study sera from 20male and female convalescent
patients aged from 8months to 33 years were obtained from
AGES BSU-Graz, Austria. Sera from control persons (sex
and age matched, without meningitis) were obtained from
the DRK Kliniken (Berlin, Germany). Detailed information
(age, sex, and diagnosis) is presented in Table 1.
2.7 Serum screening
The protein microarrays were blocked for 3 h with blocking
solution (0.05% v/v Tween 20, 3% v/v fetal calf serum (Invi-
trogen, Karlsruhe, Germany) in 16 PBS). The proteins were
later incubated with sera diluted in blocking solution (1:100)
at 47C overnight, using a volume of 200 mL for each micro-
array covered by a cover slip. The microarrays were then
washed five times for 10 min in 16 PBS and incubated with
a secondary antibody (rabbit anti-human IgG-Cy5; Dianova,
Hamburg, Germany) diluted 1:800 in blocking solution.
After 2 h of incubation, the microarrays were washed again
five times for 10 min in 16 PBS and finally in distilled water
for 5 min. The microarrays were air-dried and scanned.
2.8 Scanning
A ScanArray 4000 (Perkin Elmer Life Sciences, Cologne,
Germany) was used to scan the slides with the following
settings: laser power 100% for Cy5 649 nm excitation/emis-
sion 670 nm, photomultiplier tube (pmt) was 30–40%. The
resolution of scanning was 10 mm.
2.9 Computer analysis
For image analysis, we used GenePix Pro v 4.0 with local
background subtraction mode (Axon Instruments, Union
City, CA, USA).
2.10 Normalization method
To normalize protein microarray experiments, we used
unlabeled anti-human IgG and IgM antibodies (Sigma-
Aldrich, St. Louis, Mo, USA) in a dilution row from
16 1021–16 1024. Proteins were spotted in duplicate in
two identical fields for statistical analysis and to study intra-
microarray reproducibility.
2.11 Western blot
Proteins were transferred from the polyacrylamide gel onto a
PVDF membrane by a semidry procedure. The transfer was
carried out for 1 h at 5 mA/cm2 in blotting buffer (20 mM
Tris/HCl, pH 8.0; 150 mM glycine; 20% v/v methanol). The
membranes were then blocked with 5% w/v milk powder in
TBST (150 mM NaCl; 10 mM Tris/HCl, pH 7.5; 0.1% v/v
Tween 20) for 1 h at room temperature. The sera incubation
followed overnight at 47C in a dilution of 1:100 in blocking
reagent. The membranes were washed five times for 10 min
with TBST. The incubation with the secondary antibody
(mouse anti-human IgG; Dianova) followed for 2 h in a
dilution of 1:5000 v/v in blocking reagents at 47C. After five
wash steps with TBST for 10 min the incubation with a third
antibody (anti-mouse IgG alkaline phosphatase-conjugate;
Sigma-Aldrich), diluted 1:5000 v/v in blocking reagent for
1.5 h at 47C was carried out. Proteins were detected with 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium,
(NBT-BCIP; Sigma) and the reaction was stopped in distilled
water.
3 Results and discussion
As phase-variable genes play an important role in patho-
genicity of N. meningitidis, all such genes identified by the
groups of Saunders and Snyder [12, 13] from N. meningitidis
serogroup B were selected. For these 102 genes, primers
were designed starting with a 5’ primer to be in frame with
the expression vector. Some genes were annotated in the ge-
nome with an authentic frameshift in the gene, resulting in
the disruption of one single ORF. To solve this problem we
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Table 1. N. meningitidis phase-variable expressed proteins showing an immune response to sera of patients with meningitis. Twenty sera
were tested indicated by the number above. In the upper part of the table, additional patient sera information is presented (age:
8m indicates 8months, all other numbers are in years; sex: f, female; m, male; diagnosis: M, meningitis; S, sepsis; MS, meningitis
and sepsis; nd, not determined). After statistical calculations and considering controls from healthy persons, the factor presents
the increased antibody reaction of a diseased person. For the following proteins (NMB numbers) present on the protein micro-
arrays we could not observe an increased signal (3): 0218, 0270, 0456, 0831, 0884, 0955, 0961, 0983, 1080, 1140, 1200, 1786, 1824,
1846, 1900, 1913, 1929, 1969, 2032, 2093, 2145, 1255, 1261, 1265, 1275, 1377, 1379, 1467, 1489, 1507, 1543, 1760, and 1783
NMB Annotation according TIGR Serum number




Age of patient 17 11 20 16 33 9 2 6 9 8 14 6 17 5 19 5 19 33 8m 15
Sex of patient m m m m f m m f f f m m f f f m m m f m
Diagnosis MS nd nd M M M S MS nd M S M M M S M nd M M M
A1275 Hypothetical frameshifted protein 3
B0831 Type I restriction enzyme S protein,
degenerate 3 4
B1261 Type III restriction-modification
system EcoPI enzyme, authentic
point mutation 8
0032 Hypothetical protein 6 8 3
0053 Conserved hypothetical protein 3 8 3 3
0182 Outer membrane protein Omp85 3 3 3 22 4
0300 Hypothetical protein 10 6 3
0312 Virulence-associated protein VapA,
authentic frameshift 3
0341 tspA protein 3 4 6
0368 Hypothetical protein 4
0377 Conserved hypothetical protein 12 8 3 3
0415 Conserved hypothetical protein,
authentic frameshift 4 3 3 3 5
0432 Conserved hypothetical protein 6
0442 Opacity protein, authentic frameshift 25 3 9 19 4 3 3 9 8 25 14
0471 Conserved hypothetical protein 3 22
0486 Conserved hypothetical protein 5 3
0488 Hypothetical protein 8 3
0593 Conserved hypothetical protein 3 5 20 13
0623 Spermidine/putrescine ABC trans-
porter, periplasmic spermidine/
putrescine-binding 6
0726 Type II restriction enzyme HgaI 5 3 3 5
0741 Conserved hypothetical protein 3 5
0785 Exodeoxyribonuclease V 135 kDa
polypeptide 3 16 13
0846 LPS biosynthesis protein-related
protein 3
0872 Conserved hypothetical protein 5 3
0926 Opacity protein, authentic frameshift 4 4 5
0970 Conserved hypothetical protein 6
1001 Integrase protein, degenerate 5
1030 Conserved hypothetical protein 4 3
1053 Class 5 outer membrane protein 4
1094 Hypothetical protein 3
1223 Site-specific DNA methylase,
degenerate 9 3 6 7 7 3 4
1350 Hypothetical protein 3
1429 Outer membrane protein PorA 8
1443 DNA polymerase III, subunits gamma
and tau, programmed frameshift 3 9 3
1540 Lactoferrin-binding protein A 3
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Table 1. Continued
NMB Annotation according TIGR Serum number




Age of patient 17 11 20 16 33 9 2 6 9 8 14 6 17 5 19 5 19 33 8m 15
Sex of patient m m m m f m m f f f m m f f f m m m f m
Diagnosis MS nd nd M M M S MS nd M S M M M S M nd M M M
1636 Opacity protein, authentic frameshift 4 6 3
1734 Glutaredoxin 6 3
1741 Conserved hypothetical protein,
authentic frameshift 6 4
1836 Lipopolysaccharide biosynthesis
protein WbpC, putative 3 3
1877 Prolyl oligopeptidase family protein 3 5
1893 Conserved hypothetical protein,
authentic frameshift 7 5
1931 Hypothetical protein 5 3 4 13 12
1985 Adhesion and penetration protein 3
1988 Iron-regulated outer membrane
protein FrpB 3 5
1994 Adhesin/invasin, putative 8 7 3
1998 Serine-type peptidase 3 3
2104 mafA protein, authentic frameshift 5
used two strategies: for genes with an ORF interruption near
the 5’ end, we designed primers binding 3’ of this interrup-
tion resulting in one shortened ORF. For genes with an
interruption in the middle of the gene, we designed two
separate primer pairs flanking this disruption resulting in
the generation of two recombinant proteins for one dis-
rupted gene.
Ninety-seven percent of the selected gene constructs
could be amplified and used for cloning in an expression
vector. The identities of the clones were confirmed by se-
quencing, and correct clones were used for protein expres-
sion. The recombinant N-terminal His6-tag fusion proteins
were purified and the purification was monitored by Brad-
ford assay and SDS-PAGE (Fig. 1).
Out of the initial 102 phase-variable genes, we were able
to express and purify 91 recombinant RGS-His6 fusion-pro-
tein constructs, corresponding to 67 annotated genes, which
correlates to an overall success rate of 66%. The concentra-
tion of the purified proteins averaged around 200 mg/mL
with a size ranging from 7 kDa (NMB2145) to 160 kDa
(NMB1985). Eleven constructs, mostly transporter proteins,
did not express any protein. With one of them, NMB0098, we
experienced a bacteriostatic effect in E. coli following induc-
tion of protein expression using IPTG (data not shown).
Figure 1. SDS-PAGE of N. meningitidis proteins (Coomassie stained), after purification using a QIAGEN BioRobot 8000 in a 96-well format.
Up to 600 mg protein (eluted in 350 mL buffer) were obtained from 2 mL culture medium. Approximate sizes of the protein markers are
shown on the left in kDa.
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Figure 2. Protein microarray with 91 different recombinant bac-
terial RGS-His6 fusion-proteins spotted in duplicate on FAST
slides in a 46 4pattern (the protein NMB0057 was spotted twice
in duplicate). The recombinant RGS-His6 fusion-protein con-
structs correspond to 67 annotated genes. The microarray was
screened with anti-RGS-His antibodies, followed by the detection
with a Cy5 labeled secondary antibody. Both red and white sig-
nals indicate antibody binding, where white indicates strong and
red intermediate signals. Anti-IgG and -IgM antibodies were
spotted in dilution rows up to 1024 as standards (boxes).
For the generation of protein microarrays NC-coated
slides were used, since the 3-D structure of the coating pro-
vides a much greater binding capacity than 2-D surfaces [34,
35]. Spotting and immobilization were checked by incuba-
tion with anti-RGS-His6 antibodies, which were visualized
with Cy5-labeled secondary antibodies (Fig. 2).
For serum screening, the microarrays were incubated
with sera from patients having meningitis as well as healthy
control patients. We studied 20 patients, both female and
male, aged from 8months to 33 years as well as 12 control
patients. Normalization was performed with a set of anti-
human IgG and IgM antibody standards in accordance with
the study of Robinson et al. [32]. The results were subjected
to the 1-Sample Gaussian test and all proteins with a value
3 were accounted as targets of the immune response and
listed in Table 1. Some sera did not show any immune
responses, in twelve sera 5 proteins could be detected, in
four sera 6–10 proteins were positive, three sera yielded 10–
15 proteins, and one serum 22 different phase-variable
expressed proteins. Such a variability of the immune re-
sponse has been observed previously and is independent of
the particular person from whom the serum was obtained
[36, 37]. The reason for this is the varying susceptibility of a
particular strain to human antibody and complement.
Only the protein OpaV (NMB0442) was detected with
high reproducibility in 11 out of 20 sera (Fig. 3). This protein
OpaV shows similarities to Opa proteins. We could confirm
the results obtained by the microarray analysis by Western
blot. In Western blots the protein OpaV was detected only by
patient sera and not with the control sera (Fig. 4). Additional
protein bands that were visible in the gel represent degrada-
tion products of these proteins as proven by MS analysis
(data not shown).
The exact function of OpaV is still unknown. The TIGR
annotation (http://www.tigr.org), for this gene predicted no
protein, as it has an authentic frameshift. From the gene
homology it belongs to the group of Opa proteins. Opa pro-
teins are integral outer membrane proteins that are synthe-
sized as precursors containing signal sequences for inner
membrane transport. Parts of the leader peptide of Opa pro-
teins are encoded by repetitive coding repeats of CTTCT
pentameric units. The number of repeat units found in
genes and mRNA is subject to frequent and precise changes.
Such changes affect the expression of individual Opa genes
at the translational level [38]. A serum Opa protein is present
in Streptococcus pyogenes that is surface bound and contains
both variable and conserved domains. It was shown that this
protein is a virulence factor and leads to infection in the
pharynx [39]. This indicates a correlation to the function of
the protein OpaV. As shown for N. gonorrhoeae [40, 41], Opa
proteins play an important role in the penetration of Neisseria
into host cells as studied in cell culture experiments [40, 41].
N. meningitidis harbors four Opa proteins: OpaV
(NMB0442), NMB0926, NMB1636, and NMB1465. For
NMB1465 we could not generate a recombinant protein suc-
cessfully. The other three proteins were analyzed using pro-
tein microarrays and Western blots and have the following
degree of similarity compared to OpaV: NMB0926 (94%),
NMB1636 (78%). In Western blot analysis probed using
patient and control sera strong signals could be seen only for
OpaV and NMB0926 indicating expression during meningi-
tis (Fig. 5 and Table 1).
Figure 3. Exemplary result of a
protein microarray screened
with (A) serum of a patient and
(B) serum of a control person.
Bound serum antibodies to
spotted proteins were detected
with Cy5 labeled secondary
antibodies. White signals indi-
cate a strong antibody reaction
to the proteins OpaV (NMB0442;
arrows) and NMB2104 (circles)
that were only visible in the
patient serum.
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Figure 4. Western blot experiment screened with (A) serum
number 5 and control and (B) serum number 17 and control.
Proteins were detected using alkaline phosphatase. The addi-
tional protein bands are degradation products, as checked by MS
analysis.
Figure 5. Western blot analysis of the Opa proteins of N. meningi-
tidis screened with two patient sera and a control serum. Proteins
were detected using alkaline phosphatase. The additional protein
bands aredegradation products, as verifiedbyMSanalysis.
4 Concluding remarks
In the present study, we have investigated phase-variable
genes of N. meningitidis. Ninety-one recombinant RGS-His6
fusion-protein constructs, corresponding to 67 annotated
genes, were expressed and tested with patient sera and com-
pared to controls. Forty-seven proteins could be identified by
fluorescent signals, indicating seroreactivity. The protein
OpaV could be identified by 11 out of 20 sera, demonstrating
its immunogenicity. This indicates that this phase-variable
gene, predicted with an authentic frameshift, is expressed
during meningococcal infection.
Investigation of new potential diagnostic markers is of
outstanding interest as there is presently an upsurge of
meningococcal infection worldwide, particularly due to sero-
group B, for which still no effective vaccine is available.
Pathogen protein microarrays will become an important
tool to explore new diagnostic markers as well as for the
monitoring of immune responses to newly developed vac-
cines [42–45].
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